Plasma-Collection Network Recovery Leader

The mandate

Regulatory sampling found donor deferral and eligibility states did not propagate consistently among booking, centre and medical-review systems. Long waits drove walkouts, local teams bypassed appointment rules and several collected units entered quarantine after transport-temperature evidence failed. The network chief left when the first corrective plan treated each issue separately. The interim takes executive authority over donor and collection operations while medical and quality officers retain eligibility, release and reportability decisions.

The appointment starts within two weeks and runs ten months through regulator review, two demand peaks and a permanent search beginning in month three. The first twenty days secure donor states, quarantined units and critical centre staffing. Months two through six rebuild scheduling, centre flow, equipment, custody and transport interfaces. The final phase proves the network through an unannounced donor-state, outage and cold-chain exercise before the successor chairs eight reviews.

Handover is complete when the permanent leader has run eight reviews, sampled donor and unit journeys reconcile end to end, regulator actions have accepted evidence, and centres sustain wait and staffing thresholds without unsafe shortcuts. The successor inherits centre archetypes, donor-service risks, medical and quality dependencies, equipment and courier constraints, quarantined-unit disposition, technology limitations and a ninety-day permanent-ownership plan.

The interim may rebalance staff and appointments, suspend centre intake, change non-clinical flow, redirect approved transport, replace temporary vendors and block an operational restart lacking evidence. Donor eligibility, medical deferral, product release, regulator notification, permanent senior appointments, centre closure, collective terms or spending above USD5 million requires medical, quality, executive or board approval. Volume targets cannot override protected professional decisions.

Clinical criteria, laboratory assay policy, plasma-product manufacturing, donor compensation strategy and platform replacement are outside scope. The interim will not influence individual eligibility, release quarantined units, shorten required observation or improve yield by narrowing transparent deferral. Work concerns safe access, complete custody and dependable operation of the existing network; the independent investigation of prior control failures remains separate.

Why this seat is open

Regulatory findings joined donor service, eligibility propagation and cold-chain evidence into one systemic issue, and the original plan failed to do so. The resulting leadership departure leaves no enterprise operator across centres and transport. The group needs an experienced collection executive who can act quickly, protect medical and quality authority and leave a successor with tested control.

What you will own

• Reconcile booking, arrival, identity, eligibility state, collection, lab handoff, storage, transport and disposition journeys across donor cohorts, centres, courier handoffs and rejected units.
• Decide safe centre intake, staffing and transport allocation within delegated operational authority.
• Reset donor flow, waiting, equipment, observation and exception routines for each centre archetype.
• Establish unit custody and temperature evidence from collection through laboratory receipt and quarantine.
• Close regulator actions through sampled journeys, independent quality evidence and accountable permanent owners.
• Exercise donor-state failure, system outage, equipment loss, staffing shortage and temperature excursion.
• Induct the permanent leader and transfer centre, donor, unit, vendor and regulatory risks.

Candidate qualifications

• Has held executive authority across plasma, blood, cell collection or another regulated multi-site donor network during capacity, quality and donor-trust pressure.
• Can evidence recovery of donor flow and product custody while medical eligibility remained independent.
• Understands donor scheduling, deferral, collection, observation, cold chain, transport, quarantine and quality systems.
• Has responded to regulator action without trading evidence completeness for collection volume.
• Can distinguish donor service, completed procedure, acceptable unit and released product states.
• Has handed a scrutinised network recovery to permanent leadership after unannounced control exercises.

Non-negotiables

• Can start onsite in Houston within two weeks and visit collection centres weekly.
• Will not decide eligibility, medical deferral, unit release, reportability or laboratory policy.
• Brings direct donor-collection operating authority; general clinic operations alone is insufficient.
• Will preserve deferred, abandoned, quarantined and temperature-affected journeys in performance evidence.

1. 49 words maximum. Which donor or unit state most seriously overstated safe collection output in your recovery?
2. 49 words maximum. Confirm your earliest Houston start date and the largest regulated collection network you led.
3. 49 words maximum. How have you protected independent eligibility decisions under volume pressure?